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Excessive scarring as a consequence of healing
DANIEL A. LADIN, MD*; WARREN L. GARNER, MDb; DAVID J. SMITH, Jr., MDb
Synthesis and degradation of collagen is an essential component of wound healing . In most persons, this deposition of
collagen results in the formation of a fine line scar which restores much of the tensile strength to the injured tissue and is
cosmetically acceptable . However, in certain individuals, the result of wound healing is the excessive accumulation of
collagen, resulting in a hypertrophic scar or keloid . The precise origin of this abnormal collagen deposition is unknown, but
recent studies have begun to identify potential mechanisms for these disfiguring and painful lesions . This article will review the
clinical and laboratory findings pertinent to understanding the origin and treatment of excessive scarring . (WOUND REP REG
1995;3:6-94)
Growth, regeneration, and repair are a continuum of
processes which form new tissue . During human
embryogenesis andfetal woundhealing, dividing layers
of cells coalesce to form discrete organs and tissues.
Tissues formed in this manner increase in size while
maintaining their unique architecture . In adults, the
liver and muscle retain this ability to increase tissue
mass and regenerate through cell division . Those
tissues formed by regeneration are indistinguishable
from adjacent normal tissue . In contrast, healing of
most tissue defects is by repair and is easily identifiable
by the formation of scar .
Normal wound healing comprises a mixture of
regeneration and repair and is a highly regulated
cascade of events . Cells respond to the disruption of
their environment by the release of mediators which
stimulate chemotaxis, cellular proliferation, and the
deposition ofextracellular matrix proteins . Typically in
From the Division of Plastic Surgery, Henry Ford Hospital,
Detroit° ; and the Section ofPlastic and Reconstruc-
tive Surgery, University of Michigan, Ann Arbor'
Mich .
Reprint requests: Daniel Lodin, MD, Henry Ford Hospital,
Division of Plastic Surgery, 2799 West Grand Blvd. .
Detroit, Ml 48202.
Copyright C by The Wound Healing Society.
1067-1927195 $3.00 + 0 36/9/62723
6
IFN Interferon
TGF-(31	T nsfo minggrowth factor-(31
human skin wounds, the healing process rapidly
restores barrier function by epithelial proliferation and
develops close to normal tensile strength by collagen
synthesis and maturation .
Sometimes, the cellular processes contributing to
repair become unregulated.Apotential result is excess
matrix synthesis, which results in excessive scarring .
The adultwoundthat heals with excessive scar andthe
fetal wound that heals with no scar represent extremes
of common fundamental processes of cell proliferation
and extracellular matrix production and may reflect
differences in regulatory function .
Hypertrophic scars and keloids have likely been
present as long as human beings have been wounded.
Abnormal scarring is mentioned in the Smith Papyrus
of 2500 and 3000 B.C.' Keloid formation is depicted in
a 13th century Yoruba sculpture from West Nigeria. In
1816, Alibert first proposed the word keloid to differ-
entiate these scar excrescences from cancerous tu-
mors.' The Greek word khele, meaning crab claw, is the
root of the word describing the small claw-like projec-
tions of severe scarring extending beyond the original
wound border into normal tissue .'
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Figure 1 Earlobe keloid arising along the helical rim from earring
puncture . Note the earlobe puncture site uninvolved by keloid .
CLINICAL PRESENTATION
Hypertrophic scars and keloids occur in 5% to 15% of
wounds, and present a 5- to 15-fold higher risk to
dark-skinned people.` The clinical distinction is that
hypertrophic scars remain within the borders of the
original scar, whereas keloids extend beyond the
original scar margins.' Certain populations are more
prone to excessive scarring than others . Dark-skinned
patients between the ages of 2 and 40 years have an
increased risk ofthe development ofhypertrophic scars
or keloids. However, patients in whom keloids or
hypertrophic scars form during their childhood or
teenage years may not exhibit this tendency later in
life." Regional susceptibility to abnormal scars is
recognized . Wounds crossing skin tension lines, in
thick skin or in characteristic locations such as the
presternal and deltoid regions of the trunk and ear-
lobes, are prone to abnormal scarring (Figures 1and 2) .
Some locations such as genitalia, eyelids, palms of the
hand, and soles of the feet almost never develop
abnormal scars.'
Keloid formation occurs mainly in parts ofthebody
where the concentration of melanocytes is greatest, as
well as during times of physiologic hyperactivity in the
pituitary such as during puberty and pregnancy.lo
Keloids are not limited to the skin and, though
uncommon, have been reported on the cornea." Many
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Figure 2 Hypertrophic scar formation after burns is most marked on
the dorsal aspect of the second and third web spaces in this patient.
authors have recognized a familial tendency in keloid
formation."`
The time interval between injury and abnormal
scar formation is variable . Hypertrophic scars gener-
ally begin to develop in the weeks after injury, whereas
keloids may develop up to 1 year later. These scars are
raised, nodular, pruritic, and sometimes painful. Pa-
tients with hypertrophic scar may seek a surgeon's
attention for reasons such as local pain, itching, mass
effect, chronic superficial skin breakdown, or unsightly
appearance . In addition, function maybe compromised
when hypertrophic scarring occurs across a joint,
creating flexion contractures . In patients with keloid,
unsightly appearance, pruritus, or continued growth
may result in a consultation for plastic surgery.
Hypertrophic scars appear hyperemic, and Ehrlich and
Kelly have documented elevated blood flow in hyper-
trophic scars as long as ayear after healing." Deitch et
al . 16 noted that wounds with prolonged initial healing
have a much greater propensity to form hypertrophic
scar . This finding suggests a relationship in which a
disordered repair scheme results in disordered healing.
Hypertrophic scars may subside, whereas keloids gen-
erally do not.' Rudolph has discussed clinical differ-
encesamongwidespread scars, hypertrophic scars, and
keloids."
HISTOLOGIC ANALYSIS
Attempts have been made to histologically distinguish
hypertrophic scars from keloids. The differences are
subtle and have been summarized in previous
works.'." Keloids and hypertrophic scars differ from
normal skin andnormal scar by their rich vasculature,
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high mesenchymal density, and thickened epidermal
layer. Collagen fibers are organized in swirls . Few
macrophages are present, whereas some lymphocytes
and eosinophils are found .'° Histologic criteria charac-
teristic of keloids, not hypertrophic scar, include the
presence of broad eosinophilic refractive hyaline-like
collagen fibers .' Mucinous ground substance is abun-
dant in keloids, but fibroblast density is less than that
in hypertrophic scars. Scanning electron microscopy
shows morphologic differences. The collagen weave in
hypertrophic scars is different from that seen in
normal skin or mature scar . Collagen bundles are
flatter and less clearly demarcated, whereas fibers are
loosely arrayed in a wavy pattern, fragmented, and
shortened . The ultrastructure ofkeloids show even less
organization . Their fibers are larger and more irregu-
lar, and their interfibrillar distance is less than that
seen in hypertrophic scars. Discrete collagen bundles
are virtually nonexistent, and fibers are randomly
oriented to the epithelial surface.
The collagen nodule has been identified as a
distinguishing structural unit between hypertrophic
scar and keloid ." The nodule, which is absent from
mature scars, contains ahigh density of fibroblasts and
unidirectional collagen fibrils aligned in a highly
stressed orientation. Microvessels encircle the main
body of the nodule as a knot ; few appear within it .
Most microvessels in keloids and hypertrophic
scars are partially or fully occluded, apparently owing
to an excess of endothelial cells. Perivascular satellite
cells, some of which share a similar structure to
myofibroblasts, are also present.' 9
PATHOGENESIS
The cause of excessive scarring is multifactorial, and
various causal theories of heredity, ischemia, mechani-
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cal stretch, and hormonal, immune, or inflammatory
mechanisms have been suggested.' Because the cause
ofabnormal scars is multifactorial, emphasis should be
placed on understanding the final common cellular
pathways which are manifest as a prolongation of the
proliferative phase of wound healing . The clinical
association of delayed wound healing and abnormal
scar formation suggests that disruption of the normal
healing cascade mayresult in abnormal wound healing.
The following section§ focus on specific alterations in
cellular biochemistry, molecular biology including
growth factors, and immunology that have been noted
in keloids and hypertrophic scar .
BIOCHEMISTRY
Biochemical differences have been found in studies of
abnormal scars, mature scars, and normal skin (Table
1) . Collagen synthesis, as measured by prolyl hydroxy-
lase activity, is significantly higher in keloids than in
hypertrophic scars, and both are higher than in normal
skin." Ala-t,-okko, Rintala, and Savolainen" showed
keloid prolyl hydroxylase activity to be significantly
greater than that found in normal control skin .
Collagen synthesis in keloids is approximately 20 times
greater than that in normal unscarred skin and three
times greater than that found in hypertrophic scar."
Normal scar and skin adjacent to normal scar do not
have significantly different rates of collagen synthesis .
Craig, Schofield, and Jackson21,21 found the rate of
collagen synthesis in keloids andhypertrophic scars fall
to normal levels 2 to 3 years after injury . Cohen2' and
Harris 2' and their associates noted increased soluble
collagen in keloid scars, suggesting increased collagen
synthesis, increased degradation, or decreased cross-
linking. Knapp, Daniels, and Kaplan2' observed that
normal skin, like mature scar, had proportionally
greater content of highly cross-linked collagen than
that found in keloids. This finding is not due to
differences in lysyl oxidase, the enzyme crucial to
cross-linking . Although these results are somewhat
conflicting, these studies suggest intrinsic increases in
collagen synthesis by scar tissues. The differences may
be due to the fact that the samples were not all
normalized to cell number and were obtained at
different time periods after the initial wound. Garner
et al.28 studied ascorbate-induced collagen synthesis by
hypertrophic scar and normal dermal fibroblasts,
matched by patient and derived from clinically active
scars. The hypertrophic scar fibroblasts showed a
significant increase in collagen synthesis . The findings
of immature matrix suggest that keloids have a
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prolongation of the fibroplasia phase of wound healing
and do not progress normally into the subsequent
remodeling phase.
Collagenase activity in keloids, hypertrophic scars,
and mature scars has been shown to be greater than
that found in normal skin . Keloids show 14 times as
much collagenase activity as does normal scar, whereas
hypertrophic scar showed four times as much enzyme
activity . 2s,3o In spite of increased potential degradative
activity, a disproportionate increase in collagen synthe-
sis might lead to net deposition of extracellular matrix
and scar . Diegelmann, Bryant, and Cohen" described
the presence of the plasma proteins alpha I antitrypsin
and alpha II macroglobulin within the interstitial space
of abnormal scars. These serum proteinase inhibitors
are thought to inhibit degradation of connective tissue .
Linares and Larson12 have shown that collagen fibers
coated with chondroitin-4-sulfate are resistant to
digestion by collagenase. The overabundance of
chondroitin-4-sulfate shownby Kischer33 and Shetlar34
and their associates may contribute to the net deposi-
tion of collagen in both keloids and hypertrophic scars.
Fibronectin is an important extracellular matrix
molecule prevalent in early wound healing which later
assumes a lesser role as fibroplasia supervenes . Keloid
fibroblasts accumulate more cytoplasmic and cell sur-
face-associated fibronectin than do normal fibroblasts.
Babu, Diegelmann, and Oliver31 observed a onefold to
fourfold increase in the rate offibronectin biosynthesis
relative to that in normal cells, which could be
accounted for at the transcriptional level. Net accumu-
lation of fibronectin in these fibroblasts may cause
elevated fibronectin levels within keloid lesions . The
fibronectin receptor (the a5R1 integrin heterodimer)
was also noted to be increased within the keloid cells
relative to normal cells . The combination of increased
synthesis of fibronectin and increased expression of its
receptor suggests lack ofan inhibitory signal within the
temporal sequence of wound healing and may contrib-
ute to the continued generation of extracellular matrix
by means of integrin signaling to mesenchymal cells.
Hyaluronic acid, an important constituent of the
extracellular matrix, accumulates in fibrotic disorders
and is catabolized less effectively by hypertrophic scar
fibroblasts than by normal controls ." This situation
may be the result of a global increase in protein
synthesis. The implications of an increase in hyal-
uronic acid and fibronectin is unclear because the
extracellular matrix in fetal wounds is also rich in
hyaluronic acid and fibronectin, with type III collagen
being more abundant than type I collagen, yet those
wounds ultimately heal with scant matrix deposition .
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Molecular biology
Keloid tissues contain 32% type III collagen as
compared with 21% type III collagen present in normal
dermis .21 Cyanogen bromide-digested collagen pep
tides of keloids are similar to fetal cell digests." Type
III collagen has been postulated to be important for
stabilizing new matrix and providing scaffolding for
further healing events . Di Cesare et al . 2° point out that
the presence of immaturely cross-linked type III
collagen in keloids indicates a pathologic process in
which extracellular matrix fails to mature and achieve
normal stability . They conclude that the collagenous
extracellular matrix in keloids fails to mature, restore
its normal collagen composition, and attain stability
through cross-linking as in normal skin .
Recent studies have begun to investigate gene ex-
pression in conditions of excessive scarring (Table 2) .
Cultured fibroblasts from keloids studied by Uitto et
al." compared site-matched skin fibroblasts of healthy
age-matched patients . They noted that type I collagen
gene expression was enhanced in keloid fibroblast cul-
tures compared with controls . In addition, they noted
differences in the ratio of type I to type III procollagen
messenger RNAs. Keloid fibroblasts expressed these
mRNAs in a 22 :1 ratio (compared to a 6 :1 ratio in
controls) as a result of increased type I procollagen
expression without alteration of type III procollagen
mRNA expression . They concluded that the expression
of type I procollagen may be selectively enhanced in
keloid fibroblast cultures . The 22 : 1 ratio of type I/type
III procollagen mRNA species does not correlate to the
subsequent protein production, which may suggest
posttranscriptional alterations ofthe type I procollagen
mRNA or an increase in type I collagenolysis .
Uitto and associates further assessed type I procol-
lagen gene copy number andfound no evidence of gene
amplification, therefore suggesting that the increase in
type I procollagen mRNA occurs at the transcriptional
level." Friedman et al." also studied procollagen gene
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expression in hypertrophic scar-cultured fibroblasts,
noting increased amounts of collagen I mRNA and
similarly high transcription rates of that gene in both
fibroblast types. It is noteworthy that the procollagen
type I/type III mRNA ratio found in keloids was much
higher than that in hypertrophic scars. The authors
speculated that this difference is due to posttranscrip-
tional control of procollagen I mRNA in hypertrophic
scar but not in keloids." Ala-Kokko, Rintala, and
Savolainen" also correlated procollagen production to
expression of type I and type III procollagen mRNAs
butdid not detect overexpression of type I and type III
procollagen mRNA compared with controls . It is
noteworthy that the experiments of Ala-Kokko and
associates were carried out in white patients whose
keloid fibroblasts mayproduce less collagen . The age of
the lesions studied is also an important factor. Ala-
Kokko and associates also noted expression of type V
procollagen mRNA as well."
Recently, Peltonen et al." were able to spatially
localize gene expression within keloids using in situ
hybridization techniques . Type I procollagen gene
expression was detected along the expanding border of
the keloid lesion . The central portion of the lesions
characterized by thick coarse collagen bundles did not
show active type I procollagen gene expression . Fur-
ther within keloid lesions, numerous small blood
vessels were often surrounded by fibroblasts actively
expressing type I procollagen genes. Localization of
type III procollagen showed minimal labeling, suggest-
ing heterogeneity of expression of this gene within
keloid lesions . The authors speculated that type III
procollagen expression may be a transient phenomena
during the temporal development of a keloid lesion .
Lee" also detected type I and III but not type IV
procollagen gene expression in some fibroblasts from
keloid tissue by in situ hybridization and speculated
that clonal subpopulations are largely responsible for
procollagen production . Sollberg, Peltonen, and Uitto"
also noted that type VI procollagen mRNA was found
localized along blood vessels similar to type I collagen
mRNA but its distribution differed in that papillary
dermis also actively expressed the type VI procollagen
gene, an area devoid of type I collagen gene expression .
Type VI collagen has been suggested to play a role in
the organization of the extracellular matrix . These
results point out the heterogeneity of gene expression
within the temporal and topographic domains of an
evolving keloid lesion .
Sollberg, Peltonen, and Uitto" noted the proximity
of areas of active procollagen gene expression to blood
vessels and suggested the possibility that vascular
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damage may be one ofthe early events leading to keloid
formation . They colocalized type I procollagen mRNA
with factor-8 surface antigen expression . These find-
ings indicated that endothelium is capable of express-
ing type I procollagen genes and that the endothelial
cells may contribute to the fibrotic keloid.
Additional insight into keloid cells has been derived
from keloid cell cultures . Fibroblasts from keloids were
noted to show similar growth kinetics to those found in
normal skin and normal scar .42,43 However, Russell and
Witt43 found that keloid cells were less demandingthan
normal cells with regard to serum and growth factor
requirements and grew to higher densities." They
postulated that this reduced growth factor require-
ment could explain the exuberant growth of keloid into
tumorlike masses . Harper45 showed additional in vitro
differences in keloid fibroblast lines when contrasted to
normal fibroblasts . He noted that the in vitro life span
of a keloid fibroblast was 31% shorter than that in
normal controls. In his studies, keloid fibroblasts
reached a lower cell density than did their normal
counterparts . These studies did not stratify keloids
into age or region . Indeed, fibroblasts isolated from
different levels of the dermis, from the leading edge
versus the center, or from early keloids versus late
keloids could exhibit different growth properties and
culture. The same observations may also hold for
hypertrophic scar fibroblasts . Bertolami, Berg, and
Messadi36 observed altered growth kinetics in hyper-
trophic scar fibroblasts, noting a 69-hour doubling time
compared with 40 hours for control normal fibroblasts .
GROWTH FACTORS
Therole ofgrowth factors in the formation ofabnormal
scar remains undetermined . Growth factors may pro-
foundly influence multiple pathways involved in cell
proliferation, extracellular matrix production, and
degradation. Peltonen et al . 39 showed the presence of
transforming growth factor-R1 (TGF-R1) protein and
messenger RNA in areas of keloid activity expressing
type I and type VI procollagen genes (Figure 3) . They
speculated that TGF-R1 gene expression by neovascu-
lar endothelial cells mayactivate adjacent fibroblasts to
express additional TGF-R, as well as enhance procol-
lagen gene expression .
An altered cellular response to growth factors has
been used to define fibroblast phenotypes within
hypertrophic scars." Hypertrophic scar-derived fi
broblasts showed decreased proliferation in response to
epidermal growth factor and fetal bovine serum but not
to tumor necrosis factor alpha or platelet-derived
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growth factor . Although normal dermal fibroblasts
responded to TGF-ß with a significant elevation of
collagen synthesis, the elevated rate of collagen syn-
thesis by hypertrophic scar fibroblasts was not in-
creased further by TGF-ß l stimulation .
Tan and Peltonen" noted a decrease in collagen
synthesis as measured as hydroxy/proline synthesis by
keloid fibroblast cultures that had endothelial cell
growth factor and heparin added to the cultures . This
inhibition was noted to occur at the transcription level.
Tan et al . 47 also studied regulation of collagen and
proteoglycan expression in keloid fibroblasts in vitro
and noted that fibroblast growth factor treatment
produced similar responses in keloids and normal
dermal fibroblast control cells. Interferon (IFN) is a
factor with potential therapeutic benefit for excessive
scars. Preliminary data from Sahara et al .4a show
IFN-0t2ßmediated suppression of scar fibroblast con-
traction of collagen gels in vitro. Treatment with this
agent has also been shown to normalize keloid collagen,
glycosaminoglycan, and collagenase production in
vitro." IFN-y also has been shown to decrease cell
replication and alpha smooth muscle actin expression
in hypertrophic scar fibroblasts in vitro.5° Tredget et
al ." noted IFN-a2ßmediated suppression of types I
and III procollagen mRNA and protein production by
hypertrophic scar fibroblasts in vitro .
IMMUNOLOGYAND GENETICS
Alterations in immune cells and immunologic function
have been suggested as causes for excessive scarring .
Keloids may be the result of an immune reaction to
skin antigens, sebum, melanin, blood products, or
foreign bodies .' Differences in immunoglobulin levels
have been shown within keloid scars.52 Inflammatory
cells found within abnormal scar may play important
regulatory roles in the fibrogenic process." In particu-
lar, mast cells may play a regulatory role in abnormal
scars and have been found interspersed along dermal
collagen bundles in keloids."," Histamine levels are
increased in keloid tissue, which may enhance the
formation of collagen. Histamine is also a competitive
inhibitor of lysyl oxidase, which can explain the
abnormal cross-linkage formation shown in collagen
and the increased amounts of soluble collagen in
keloids.26
Castagnoli et al.16 recently characterized hyper-
trophic scars and noted dense infiltrates of
interleukin-2 receptor-positive cells and abundant
Langerhans cells in epidermis and dermis ; this sug-
gests an important role ofimmunologic mechanisms in
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Figure 3 Demonstration of TGF-p, gene expression in keloid tissue .
In situ hybridizations were performed with a single-stranded cRNA
probe. Note that the autoradiographic grains, representative of
(3213) cRNA-mRNAhybrids, are associated with (A) fibroblasts (arrows),
and with (B) endothelial cells of capillaries (arrows) . L denotes the
lumen of the blood vessel . The area outlined by the box (A) is
enlarged in B. Bars: A, 100 wm ; B, 20 wm . Reprinted with permission
of Elsevier Science Inc. from Peltonen et al ., The Journal of
Investigative Dermatology, vol. 97, p. 247. Copyright 1991 by The
Society for Investigative Dermatology, Inc.
hypertrophic scar formation . It is noteworthy that
fibroblasts and keratinocytes were observed to express
class II antigens in hypertrophic scars, but whether
they are involved in antigen presentation is a point of
speculation. The T-cell population may play an impor-
tant role in pathogenesis of abnormal scars because
persistent perivascular lymphocytes have been seen in
abnormal scars associated with increased collagen
deposition." Conversely, mice depleted of T-cells show
depressed wound healing ability as assessed by bone
breaking strength and collagen synthesis." McCauley
et al." established differences in cytokine production
by peripheral blood mononuclear cells present in keloid




Figure 4 Hypertrophic scarring from burns treated with a combina-
tion of compressive garments and silicone gel placed in the dorsal
web spaces (same patient as seen in Figure 2) .
immunoregulation by inflammatory cells rather than
primary fibroblast alterations play a significant role in
keloid formation .
A genetic predisposition for keloid formation has
been recognized, particularly in individuals with mul-
tiple lesions, with both autosomal dominant and
recessive modes of inheritance reported . 12,13 Thepreva-
lence of several HLA-B and HLA-D loci have been
shown at increased levels in patients with keloid" The
human leukocyte antigen-DR beta 16 allogenotype has
been associated with a 12-fold increased risk for
hypertrophic scar formation.61
THERAPY
Optimal therapy for excessive scarring has yet to be
established. Treatment is empiric, and all modalities
are plagued by high recurrence rates, especially in
patients with keloid . Current therapy for keloids
consists of surgical excision or nonsurgical treatment
including radiotherapy and corticosteroid injection.
This subject was recently reviewed by Lawrence,' who
compared relative efficiencies of the various treat-
ments for keloids. DNA analysis has been used to
predict clinical behavior of soft tissue tumors,62 and
aneuploid keloids have been noted to have a greater
propensity for recurrence.63 Optimal treatment of
keloids may be guided by recurrence potential, with
more modalities combined for the most difficult le-
sions.
Treatment for hypertrophic scars similarly involves
surgical excision and nonsurgical therapy. Surgical
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treatment focuses on reduction of inflammation
through early wound closure and on alteration of
biochemical forces on the scar through interposition of
unscarred skin along tension lines. Among nonsurgical
therapies for excessive scars, use of topical silicone,"
compression therapy," and steroid injections" are of
documented benefit (Figure 4) .
The abundance of empiric treatment modalities for
excessive scarring attest to the lack ofunderstanding of
the pathogenesis of this clinical condition . Treatment
strategies directed toward specific alterations in the
keloid or hypertrophic scar cell biology will offer the
best choice for therapeutic efficacy . For example,
blockade of a growth factor with known matrix-
stimulating properties such as TGF-ß would reduce
accumulation of scar tissue . Shah, Foreman, and
Ferguson" recently showed that scar formation in
normal incisional murine wounds could be limited by
antibodies blocking TGF-ß." There have also been
promising trials with IFNin the treatment ofexcessive
scar . Uncontrolled trials with the use of IFN-y in the
treatment of hypertrophic scarrings' and IFN-(x,,
treatment of keloids4' suggest beneficial effects on
resolution of these lesions. A small controlled trial of
keloid treatment with intralesional injection of IFN-y
showed significant reduction in lesion height." IFN-y
also was effective in reducing symptoms and scar size
in patients with hypertrophic scar."
At the present time, no simple cure exists for
excessive scarring. It is also difficult to postulate a
discrete mechanism responsible for this type of scar
formation. Recent advances in molecular biology and
biochemistry have provided some detailed descriptive
information but have not provided a unifying hypoth-
esis . Overall, hypertrophic scarring seems to be the
result of disordered normal healing, a process caused
by intrinsically normal cells reacting to exogenous
stimuli such as prolonged inflammation or biochemical
force. Keloids, on the other hand, may arise in the
absence of significant exogenous stimuli and, as such,
may be considered to have some endogenous tendency
toward excessive scar formation . In both cases, a
multifactorial origin is likely . It seems reasonable to
prevent prolonged exogenous stimulation of a healing
wound and to treat excessive scar formation with
combined modalities . Specific endogenous factors driv-
ing keloid scar formation maybe identified, and specific
pharmacotherapy can then be designed to limit those
processes . These therapies will ultimately promote
degradation or limit production of extracellular matrix
within the scar. Treatment strategies targeting specific
growth factor receptors or matrix genesmayultimately
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provide the most useful therapy for excessive scar
formation.
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